Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
India
/
Pharmaceuticals & Biotech
Create a narrative
Mankind Pharma Community
NSEI:MANKIND Community
3
Narratives
written by author
0
Comments
on narratives written by author
15
Fair Values set
on narratives written by author
Community Investing Ideas
Mankind Pharma
Popular
Undervalued
Overvalued
Mankind Pharma
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Rising Regulatory Hurdles And Pricing Restrictions Will Undermine Future Prospects
Key Takeaways Reliance on low-margin domestic generics and regulatory shifts risks eroding margins and threatens long-term profit sustainability. Limited global presence and lag in digital healthcare adoption expose the company to heightened market and competitive vulnerabilities.
View narrative
₹2.15k
FV
15.0% overvalued
intrinsic discount
12.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Mankind Pharma
AN
AnalystHighTarget
Consensus Narrative from 17 Analysts
India's Rising Middle Class And Urbanization Will Reshape Healthcare Markets
Key Takeaways Strong specialty biologics portfolio, innovative pipeline, and rapid execution position the company for accelerated margin and earnings growth ahead of consensus expectations. Expanding distribution, premium consumer brands, and robust R&D create a structural edge to capitalize on rising healthcare demand and chronic disease prevalence.
View narrative
₹3.30k
FV
25.1% undervalued
intrinsic discount
16.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Mankind Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
Key Takeaways Strong focus on high-margin chronic therapies, consumer health growth, and specialty drugs positions the company for sustained revenue expansion and improved earnings quality. Enhanced operational efficiency, R&D investment, and expanding modern trade presence support scalable profitability and mitigate future margin pressures.
View narrative
₹2.80k
FV
11.7% undervalued
intrinsic discount
14.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
MANKIND
MANKIND
Mankind Pharma
Your Fair Value
₹
Current Price
₹2.47k
15.1% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
237b
2015
2018
2021
2024
2025
2027
2030
Revenue ₹237.1b
Earnings ₹34.8b
Advanced
Set Fair Value